secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001104659-23-116307
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents Q3 product sales up 20% to $7.8M, gross margin improves to 72%, STAR-T data expected year-end
--------------------------------------------------------------------------------

- Q3 product sales $7.8M (+20% YoY); total revenue $8.8M (+9% YoY).
- Product gross margin 72% vs 55% a year ago, driven by manufacturing efficiencies.
- Pivotal STAR-T trial database lock nearing; initial data analysis expected before year-end.
- Cash and restricted cash $10.0M; company exploring alternative financing after terminating equity offering.
- Over 221,000 CytoSorb devices delivered cumulatively; expansion in Brazil approved for shock treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465923116307/0001104659-23-116307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465923116307/tm2330311d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer